25 February 2018 - Hummingbird Bioscience, a preclinical-stage drug development company focused on novel cancer immuno-therapeutics, has been featured on the Biotech Strategy Blog discussing its pipeline of CD47 bispecific molecules targeting AML and MM.
A feature-length interview undertaken with CEO Piers Ingram is available at the Biotech Strategy Blog providing an in-depth discussion of the scientific rationale behind targeting CD47 signals and the unique benefits Hummingbird Bioscience bispecific approaches have in AML and MM.